scholarly journals Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas

Head & Neck ◽  
2005 ◽  
Vol 27 (3) ◽  
pp. 182-186 ◽  
Author(s):  
Daniel Taussky ◽  
Pavel Dulguerov ◽  
Abdelkarim S. Allal
Keyword(s):  
Head And Neck ◽  
Salvage Surgery ◽  
Accelerated Radiotherapy ◽  
Head And Neck Carcinomas ◽  
Concomitant Boost

Late Local Treatment Morbidity after Accelerated Radiotherapy or Alternating Chemoradiotherapy for Advanced Head and Neck Carcinoma

2002 ◽  
Vol 88 (4) ◽  
pp. 313-320 ◽  
Author(s):  
Giuseppe Sanguineti ◽  
Maria Pia Sormani ◽  
Marco Benasso ◽  
Renzo Corvò ◽  
Franca Foppiano ◽  
...  
Keyword(s):  
Head And Neck ◽  
Phase Ii ◽  
Local Treatment ◽  
Late Toxicity ◽  
Advanced Head ◽  
Accelerated Radiotherapy ◽  
Local Toxicity ◽  
End Of Treatment ◽  
Concomitant Boost

Background To report local long-term morbidity after concomitant boost radiotherapy (AFRT) or alternating chemoradiotherapy (CTRT), we analyzed the toxicity data recorded in 168 patients with advanced head and neck squamous cell carcinoma treated at our institution within phase II-III studies. Patients and Methods All patients enrolled in three consecutive phase II-III studies and followed for a minimum of three months after the end of treatment were included in the present analysis. Local late reactions were scored prospectively. The actuarial incidence of grade 2 or more (2-4) late local toxicity according to RTOG/EORTC was taken as endpoint. The median follow-up is 32.0 months (range, 3.3-138.1 months). For living patients the minimum and median follow-up are 12.1 and 69.3 months, respectively. Results The five-year actuarial incidence of grade 2+ and grade 3+ toxicity are 56.7 ± 5% and 21 ± 4%, respectively. At multivariate analysis, acute mucositis grade, complementary surgery, primary site and performance status proved to be independent predictive factors of grade 2+ late toxicity with P values of <0.001, 0.009, 0.022 and 0.033, respectively. No effect was found for treatment itself on the incidence of late toxicity, although patients treated with accelerated radiotherapy had a higher probability of confluent mucositis than patients treated with alternating chemoradiotherapy (68% vs 32%, P <0.01). Conclusions A substantial proportion of surviving patients develops late complications, although severe irreversible reactions occur in a minority of patients. Acute local toxicity can be used to predict local late toxicity that arises within five years of the end of treatment.

Feasibility and outcome of a progressively accelerated concomitant boost radiotherapy schedule for head and neck carcinomas

1997 ◽  
Vol 38 (4) ◽  
pp. 685-689 ◽  
Author(s):  
Abdelkarim S. Allal ◽  
Sabine Bieri ◽  
Raymond Miralbell ◽  
Francis Marchal ◽  
Willy Lehmann ◽  
...  
Keyword(s):  
Head And Neck ◽  
Head And Neck Carcinomas ◽  
Concomitant Boost ◽  
Boost Radiotherapy

A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas

2006 ◽  
Vol 79 (1) ◽  
pp. 34-38 ◽  
Author(s):  
José Antonio Medina ◽  
Antonio Rueda ◽  
Antonio Sacchetti de Pasos ◽  
Jorge Contreras ◽  
Manuel Cobo ◽  
...  
Keyword(s):  
Head And Neck ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Head And Neck Carcinomas ◽  
Concomitant Boost ◽  
Boost Radiation ◽  
Weekly Cisplatin

48 Tolerance and results of a modified concomitant boost radiotherapy schedule in head and neck carcinomas

1996 ◽  
Vol 40 ◽  
pp. S15
Author(s):  
A.S. Allal ◽  
S. Bieri ◽  
R. Miralbell ◽  
S. Balmer-Majno ◽  
F. Marchal ◽  
...  
Keyword(s):  
Head And Neck ◽  
Head And Neck Carcinomas ◽  
Concomitant Boost ◽  
Boost Radiotherapy
Sign in / Sign up

Export Citation Format

Share Document